New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
暂无分享,去创建一个
F. Bertucci | C. Vicier | A. Gonçalves | R. Sabatier | E. Mezni | M. Guérin
[1] Qingyuan Zhang,et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. , 2015, The Lancet. Oncology.
[2] J. Baselga,et al. A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. , 2012 .
[3] Jian Zhang,et al. Abstract P1-18-16: A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer , 2020 .
[4] G. Rowse,et al. Abstract 31: Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers , 2017 .
[5] H. Kohrt,et al. Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment , 2015, ImmunoTargets and therapy.
[6] Carsten Denkert,et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.
[7] N S El Saghir,et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] U. Banerji,et al. 333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985 , 2015 .
[9] P. Carter,et al. Antibody-drug conjugates in cancer therapy. , 2013, Annual review of medicine.
[10] R. Greil,et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.
[11] Sohita Dhillon. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU , 2019, Clinical Drug Investigation.
[12] D. Bergstrom,et al. Abstract 48: Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate , 2017 .
[13] C. Perou,et al. Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer , 2014, Journal of the National Cancer Institute.
[14] Michael Hogarth,et al. Adaptive Randomization of Neratinib in Early Breast Cancer. , 2016, The New England journal of medicine.
[15] Deborah H Anderson,et al. Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice , 2012 .
[16] Peng Yuan,et al. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial , 2019, Clinical Cancer Research.
[17] A. Rademaker,et al. Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy. , 2017 .
[18] François Bertucci,et al. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. , 2017, European journal of cancer.
[19] R. Gelber,et al. Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-pos , 2020 .
[20] C. Dumontet,et al. Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.
[21] J. Ajani,et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. , 2018 .
[22] S. Berger,et al. Abstract 556: Costimulatory T-cell engagement by the HER2/CD137 bispecific PRS-343 leads to strong antitumor effect in humanized mouse model , 2016 .
[23] J. Bergh,et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer , 2010, Breast Cancer Research and Treatment.
[24] R. Bartsch,et al. ASCO 2018: highlights in HER2-positive metastatic breast cancer , 2018, memo - Magazine of European Medical Oncology.
[25] S. J. Schrieber,et al. FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer , 2014, Clinical Cancer Research.
[26] R. Pazdur,et al. U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer , 2018, Clinical Cancer Research.
[27] Sung-Bae Kim,et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] B. Hentschel,et al. FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis , 2020, Cancers.
[29] John M Lambert,et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.
[30] M. Chamberlain,et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.
[31] Sung-Bae Kim,et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. , 2016, JAMA oncology.
[32] J. Karlsson,et al. Abstract 5857: HER2-targeted thorium-227 conjugate (HER2-TTC): Efficacy in a HER2 positive orthotopic bone model , 2017 .
[33] P. Moore,et al. Abstract 1538: Margetuximab mediates greater Fc-dependent anti-tumor activities than trastuzumab or pertuzumab in vitro , 2019, Immunology.
[34] B. Ramaswamy,et al. PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer , 2018, The breast journal.
[35] F. André,et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] E. Winer,et al. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] C. Redfern,et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. , 2018 .
[38] Wei Li,et al. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Sung-Bae Kim,et al. A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial , 2018, International journal of cancer.
[40] M. Buyse,et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2016, The Lancet. Oncology.
[41] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.
[42] D. Slamon,et al. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer , 2018, Molecular Cancer Therapeutics.
[43] E. D. de Vries,et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. , 2019, The Lancet. Oncology.
[44] U. Banerji,et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. , 2018 .
[45] A. Prat,et al. SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer. , 2018 .
[46] W. Gradishar,et al. SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). , 2019, Journal of Clinical Oncology.
[47] C. Redfern,et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.
[49] J. Dering,et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.
[50] M. Owens,et al. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.
[51] G. Giaccone,et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] R. García-Becerra,et al. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. , 2015, American journal of cancer research.
[53] H. Yao,et al. Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study. , 2019, Journal of Clinical Oncology.
[54] P. Loo,et al. Abstract LB-261: Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2:HER3 heterodimer , 2015 .
[55] S. Keam. Trastuzumab Deruxtecan: First Approval , 2020, Drugs.
[56] Y. Bang,et al. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors , 2017, Cancer research and treatment : official journal of Korean Cancer Association.
[57] M. Greene,et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. , 2010, Cancer cell.
[58] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.
[59] A. Iannello,et al. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies , 2005, Cancer and Metastasis Reviews.
[60] W. Gradishar,et al. Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort. , 2019, Journal of Clinical Oncology.
[61] Julien Torgue,et al. Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab , 2014, The Journal of Nuclear Medicine.
[62] Giulia Bianchi,et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[63] C. Isaacs,et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.
[64] M. Chamberlain,et al. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial , 2018, JAMA oncology.
[65] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[66] A. Kitano,et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. , 2017, The Lancet. Oncology.
[67] J. Isola,et al. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. , 2020, Cancer letters.
[68] P. Moore,et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties , 2011, Breast Cancer Research.
[69] W. Gradishar,et al. Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis , 2020 .
[70] D. Davițoiu,et al. "Triple positive" breast cancer - a novel category? , 2017, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.
[71] A. Tutt,et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.
[72] Stephen C Alley,et al. Antibody-drug conjugates: targeted drug delivery for cancer. , 2010, Current opinion in chemical biology.
[73] E. Winer,et al. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] A. Giobbie-Hurder,et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. , 2019, The Lancet. Oncology.
[75] A. Musolino,et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] J. Schellens,et al. First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC). , 2017 .
[77] J. Karlsson,et al. Abstract 5859: HER2-targeted thorium-227 conjugate (HER2-TTC): Efficacy in preclinical models of trastuzumab and T-DM1 resistance , 2017 .
[78] C. Isaacs,et al. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] Tiansen Li,et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. , 2006, Cancer cell.
[80] S. Chia,et al. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC) , 2017, Clinical Cancer Research.
[81] J. Baselga,et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] E. Winer,et al. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. , 2019, Journal of Clinical Oncology.
[83] E. Perez,et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer , 2019, BMC Cancer.
[84] Tuan S. Nguyen,et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. , 2016, Cancer discovery.
[85] Peng Yuan,et al. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] P. Morris,et al. A phase Ib trial of copanlisib and tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”. , 2018 .
[87] S. Loi,et al. Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC) , 2019, Poster Discussion Abstracts.
[88] F. André,et al. Abstract OT2-07-02: Trastuzumab deruxtecan (DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 study , 2019, Ongoing Clinical Trials.
[89] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[90] Yan Sun,et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] H. Wildiers,et al. B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer. , 2019, Journal of Clinical Oncology.
[92] C. Klein,et al. p95HER2–T cell bispecific antibody for breast cancer treatment , 2018, Science Translational Medicine.
[93] Sung-Bae Kim,et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. , 2019, Journal of Clinical Oncology.
[94] S. Verma,et al. Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study , 2019, Ongoing Clinical Trials.
[95] C. Redfern,et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. , 2019, The Lancet. Oncology.
[96] L. Matis,et al. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343 , 2019, Clinical Cancer Research.
[97] M. Berger,et al. Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC). , 2015 .
[98] Sung-Bae Kim,et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. , 2020, The Lancet. Oncology.
[99] M. Irving,et al. Infigratinib in Children With Achondroplasia (ACH): Design of PROPEL2 - A Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study , 2021 .
[100] Xin Li,et al. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[101] Young-Kwang Yoon,et al. Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells , 2012, Anti-cancer drugs.
[102] M. Buyse,et al. NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC). , 2018 .